CBD During Pregnancy and Breastfeeding: What You Need to Know

The intersection of CBD pregnancy safety is one of the most important and most under-discussed topics in cannabinoid education. As CBD has become mainstream, available in grocery stores, pharmacies, and wellness shops, many women who have been using CBD for anxiety, sleep, pain, or general wellness face a difficult question when they become pregnant or begin breastfeeding: is it safe to continue? The answer from every major medical organization is clear and unanimous: no, or at least not until substantially more research has been conducted. Yet this advice exists in tension with the reality that pregnancy and the postpartum period are times of heightened anxiety, sleep disruption, nausea, and pain, the very conditions for which many women were using CBD in the first place.

The challenge with CBD pregnancy safety is that the absence of evidence of harm is not the same as evidence of absence of harm. Because ethical constraints prevent exposing pregnant women and developing fetuses to experimental compounds in clinical trials, virtually all of the evidence for CBD’s effects on fetal development comes from animal studies, observational data from cannabis-using pregnant women (where CBD cannot be isolated from THC exposure), and our understanding of the endocannabinoid system’s role in fetal development. This evidence is concerning enough that the precautionary principle applies, when the potential consequences include harm to a developing fetus or nursing infant, the bar for safety assurance must be extraordinarily high.

This article explains why medical organizations advise against CBD use during pregnancy and breastfeeding, examines the biological mechanisms that underlie these concerns, reviews the available research, and discusses safer alternatives for the symptoms that women often use CBD to manage during the perinatal period.

Why Medical Organizations Advise Against CBD in Pregnancy

Official Positions from FDA, ACOG, and AAP

The U.S. Food and Drug Administration (FDA) issued a direct advisory stating: “FDA strongly advises against the use of cannabidiol (CBD), tetrahydrocannabinol (THC), and marijuana in any form during pregnancy or while breastfeeding.” The advisory cites potential risks to fetal brain development and notes that CBD products may contain undisclosed THC or other contaminants, adding additional layers of risk beyond CBD itself.

The American College of Obstetricians and Gynecologists (ACOG) recommends that physicians counsel pregnant and lactating women to discontinue all cannabis-derived product use, including CBD, due to insufficient evidence of safety. ACOG specifically notes that pregnant women should not use cannabis or its derivatives as a treatment for nausea or other conditions during pregnancy. The American Academy of Pediatrics (AAP) takes a similar position regarding breastfeeding, advising nursing mothers to avoid all cannabis-derived products because cannabinoids are lipophilic and can be transferred to infants through breast milk.

These advisories are significant because they come from the medical organizations responsible for maternal and infant care standards in the United States. They are not based on documented cases of CBD-specific harm in pregnant women, which largely do not exist because the research has not been conducted, but rather on the precautionary principle combined with concerning preclinical data and the known biology of the endocannabinoid system during fetal development.

The Endocannabinoid System in Fetal Development

Why External Cannabinoids Pose Theoretical Risks

The biological concern about CBD pregnancy exposure centers on the endocannabinoid system’s critical role in fetal development. The ECS is one of the earliest signaling systems to emerge during embryonic development, and it plays essential roles in processes that occur during very specific developmental windows. CB1 receptors appear in the fetal brain by the 14th week of gestation and are involved in neural progenitor cell proliferation, neuronal migration (the process by which newly formed neurons move to their correct positions in the developing brain), axon guidance (the process by which developing neurons extend connections to appropriate targets), and synaptogenesis (the formation of synaptic connections between neurons).

Endocannabinoid signaling is also essential for embryo implantation in the uterine wall, one of the earliest and most critical steps in pregnancy. Studies published in Human Reproduction have shown that precise anandamide levels are required for successful implantation: too much or too little anandamide disrupts the implantation window. The placenta itself is rich in endocannabinoid receptors and produces endocannabinoids that regulate placental development, nutrient transfer, and protection of the fetal-maternal interface. Any external compound that modulates endocannabinoid signaling, by inhibiting FAAH (as CBD does), altering receptor activity, or introducing exogenous receptor ligands, has the theoretical potential to disrupt these finely tuned developmental processes.

This does not mean that CBD has been proven to cause developmental harm in humans. But the biology makes clear that the endocannabinoid system is not a peripheral wellness system during fetal development, it is an essential developmental signaling network with precise spatial and temporal regulation. Introducing a FAAH inhibitor (CBD) that raises anandamide levels during a developmental window that requires precise anandamide concentrations carries inherent theoretical risk, even if the practical risk at a given dose remains unknown.

What the Animal and Observational Research Shows

Preclinical Evidence of Developmental Concerns

Animal studies examining CBD’s effects on fetal development have produced concerning findings. A study from the FDA’s National Center for Toxicological Research found that high-dose CBD administration to pregnant rats produced developmental toxicity, including reduced fetal body weight and skeletal variations. Another preclinical study published in Toxicology and Applied Pharmacology found that CBD exposure during the prenatal period affected the developing male reproductive system in rats, reducing testicular size and sperm production at doses that were not toxic to the mothers. While these studies used doses significantly higher than typical human consumer doses (often 75-150mg/kg in animals, compared to 0.5-1mg/kg for a typical human consumer), they demonstrate that CBD is biologically active in the developing organism and can affect developmental processes at sufficient doses.

Observational human data on cannabis use during pregnancy is available but cannot isolate CBD from THC. Studies of cannabis-using pregnant women have found associations with lower birth weight, preterm delivery, and altered neurodevelopmental outcomes in offspring, but these women were using whole cannabis products containing THC, CBD, and dozens of other compounds. The contribution of CBD specifically to these outcomes is impossible to determine from observational data, and it would be inappropriate to attribute the observed risks entirely to CBD. However, the data does not provide reassurance either: no study has examined the safety of isolated CBD in pregnant women because no ethical review board would approve such a study given the current level of uncertainty.

CBD Transfer Through Breast Milk

For breastfeeding mothers, the concern is that CBD and its metabolites can transfer to the infant through breast milk. Cannabinoids are highly lipophilic (fat-soluble), and breast milk has a high fat content, creating an efficient transfer medium. A 2018 study published in Pediatrics detected cannabinoids in 63% of breast milk samples from cannabis-using mothers, with detectable levels persisting for up to six days after last use. While this study measured THC rather than CBD specifically, CBD’s similar lipophilicity suggests comparable transfer kinetics. The developing infant’s liver has immature CYP450 enzyme systems, meaning their ability to metabolize CBD is substantially reduced compared to adults, potentially resulting in higher effective exposures from lower doses transferred through breast milk.

The CBD Pregnancy Product Quality Dimension

Additional Risks from Unregulated CBD Products

Beyond CBD’s own uncertain safety profile in pregnancy, the unregulated nature of the CBD market introduces additional risks for pregnant and breastfeeding women. The 2017 JAMA study documenting that 70% of CBD products are mislabeled means that a pregnant woman using what she believes is a THC-free CBD product may unknowingly be exposing her developing fetus to THC, a compound with well-documented effects on fetal brain development. Heavy metals, pesticides, residual solvents, and microbial contaminants that may be present in poorly manufactured CBD products pose additional teratogenic and toxic risks that do not apply to properly manufactured pharmaceutical products.

This product quality concern amplifies the risk calculus for pregnant women specifically. Even if pure CBD were eventually shown to be safe during pregnancy at certain doses, the current inability to guarantee product purity and accurate labeling across the consumer market means that “CBD use during pregnancy” currently means “exposure to an uncertain mixture of CBD, potential THC, and potential contaminants”, a risk profile that responsible healthcare providers cannot endorse.

Safer Alternatives for Pregnancy Symptoms

Evidence-Based Options for Nausea, Pain, Anxiety, and Sleep

Women who were using CBD before pregnancy for nausea, anxiety, pain, or sleep often need alternative approaches during the perinatal period. For pregnancy nausea, ginger supplements (250mg four times daily) have an evidence base supporting their safety and efficacy in pregnancy. Vitamin B6 (pyridoxine, 25mg three times daily) is recommended by ACOG as a first-line treatment for nausea and vomiting. For anxiety, evidence-based approaches include cognitive behavioral therapy (CBT), mindfulness-based stress reduction programs, and, when necessary, medications like sertraline (Zoloft) that have extensive safety data in pregnancy. For sleep disruption, sleep hygiene optimization, magnesium supplementation (which has favorable pregnancy safety data), and, when necessary, medications approved for pregnancy use can be discussed with an obstetrician. For pain, acetaminophen remains the safest analgesic during pregnancy when used at recommended doses, complemented by physical therapy, prenatal yoga, and manual therapies.

The key message for pregnant and breastfeeding women who have been using CBD is: the conditions you were treating did not disappear when you conceived, and you deserve effective treatment, but the treatment options during pregnancy must be evaluated through the lens of fetal safety rather than personal convenience. Discuss your symptoms and your prior CBD use openly with your obstetrician so they can recommend evidence-based alternatives that have established pregnancy safety profiles.

Planning for Postpartum Return to CBD

For women who found CBD beneficial before pregnancy and plan to resume use after the perinatal period, the timeline depends on whether they are breastfeeding. If formula feeding, CBD can generally be resumed after delivery once medical clearance is obtained and any postpartum medications have been evaluated for interactions. If breastfeeding, the same precautions that apply during pregnancy continue to apply throughout the lactation period, CBD’s lipophilicity and the developing infant’s immature metabolic capacity remain concerns regardless of whether the infant is one week old or one year old. The safe resumption of CBD should be discussed with a healthcare provider who can evaluate the specific circumstances, including whether the infant has any health conditions that might increase sensitivity to CBD exposure through breast milk.

Women who used CBD before pregnancy for chronic conditions like anxiety or pain should also consider that the hormonal changes of pregnancy and postpartum can significantly alter the conditions themselves. Postpartum anxiety and depression affect an estimated 10-20% of new mothers and may require different treatment approaches than pre-pregnancy anxiety. The postpartum hormonal transition can also alter the endocannabinoid system itself, potentially changing how a woman responds to CBD compared to her pre-pregnancy experience. Working with a healthcare provider to reassess symptoms and treatment options postpartum, rather than simply resuming the pre-pregnancy CBD regimen, is the most prudent approach.

What Researchers Still Need to Determine

The Knowledge Gaps That Need Closing

The current recommendation against CBD use during pregnancy is driven as much by what we do not know as by what we do know. Several critical questions remain unanswered. First, what are the effects of pure, pharmaceutical-grade CBD (without THC contamination) on human fetal development at the doses typically used by consumers? Animal studies use much higher doses than human consumers, and the relevance of high-dose animal data to low-dose human exposure is uncertain. Second, does the timing of CBD exposure during pregnancy matter, is there a critical window during which the developing fetus is more or less vulnerable to endocannabinoid system modulation? Third, what are the actual concentrations of CBD and its metabolites that transfer through breast milk, and what are the resulting plasma levels in nursing infants?

These questions cannot be answered through traditional randomized controlled trials because of the ethical impossibility of intentionally exposing pregnant women to experimental compounds. Instead, researchers are pursuing prospective observational studies that follow women who have self-selected to use CBD during pregnancy and compare their outcomes to matched controls. Registry-based studies, pharmacokinetic modeling of breast milk transfer, and long-term neurodevelopmental follow-up of exposed infants will eventually provide the data needed to refine the current blanket advisory. Until that data is available, the precautionary principle remains the foundation of medical advice on CBD pregnancy safety, and rightfully so.

Conclusion

The consensus of the FDA, ACOG, and AAP is clear: CBD should be avoided during pregnancy and breastfeeding. This recommendation is based not on documented cases of harm from pure CBD in pregnant women, which do not exist because the research has not been conducted, but on the precautionary principle applied to the known biology of the endocannabinoid system in fetal development, concerning preclinical data, the inability to guarantee product purity in the current market, and the potential for breast milk transfer to nursing infants.

For women who have been benefiting from CBD for anxiety, pain, or sleep, the transition away from CBD during pregnancy can feel frustrating. But the stakes, the healthy development of a fetus or the safety of a nursing infant, are uniquely high, and the current evidence is not sufficient to provide meaningful reassurance. Effective alternatives exist for every symptom CBD is commonly used to address during the perinatal period.

The Bottom Line: Until definitive human safety data exists, the responsible course is to discontinue CBD during pregnancy and breastfeeding and work with your healthcare provider to find pregnancy-safe alternatives for the symptoms you were managing with CBD.